ITeos Therapeutics Announces Appointment of Dr. Bruno Montanari to the Company's Board of Directors

Share Article

ITeos Therapeutics SA announced today the appointment of Bruno Montanari, PharmD, to the company's board of directors. Dr. Montanari adds further depth to iTeos' board by bringing knowledge and experience gained through a long investment career in the life sciences sector.

ITeos Therapeutics SA announced today the appointment of Bruno Montanari, PharmD, to the company's board of directors. Dr. Montanari adds further depth to iTeos' board by bringing knowledge and experience gained through a long investment career in the life sciences sector.

"We are delighted to welcome Dr. Montanari to our board of directors," said Dr Philippe Guinot, iTeos Therapeutics’ Chairman. "His extensive investment experience in our industry, network and insight will prove invaluable as we continue to build iTeos as a leader in the field of oncology."

Dr. Montanari graduated as a PharmD from Université René Descartes (Paris V) and holds a Masters degree from Ecole des Hautes Etudes Commerciales (HEC, Paris). Since 1999, he held various positions in the healthcare groups of Deutsche Bank and Merrill Lynch investment banking divisions, to later embrace venture capital with CDP Capital and Atlas Venture. He currently is a Director in the venture team of Omnes Capital (formerly known as Crédit Agricole Private Equity), which he joined in 2010.

About iTeos Therapeutics SA
Originating from a partnership between Ludwig Cancer Research and de Duve Institute at the Université Catholique de Louvain, iTeos Therapeutics SA (http://www.iteostherapeutics.com) is a private biotechnology company targeting the metabolism of the tumor microenvironment for the development of innovative immuno-oncology therapeutics. In December 2014, iTeos partnered with Pfizer Inc. for the development of its IDO1 and TDO2 drug candidates, as well as to discover and validate new targets involved in cancer immunosuppression. iTeos is currently expanding its pipeline’s programs to develop innovative immunomodulators for different cancer indications.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Alfred Gray
Visit website